Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

Once melanomas have progressed with acquired resistance to mitogen-activated protein kinase (MAPK)-targeted therapy, mutational heterogeneity presents a major challenge. We therefore examined the therapy phase before acquired resistance had developed and discovered the melanoma survival oncogene MIT...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Michael P., Brunton, Holly, Rowling, Emily J., Ferguson, Jennifer, Arozarena, Imanol, Miskolczi, Zsofia, Lee, Jessica L., Girotti, Maria R., Marais, Richard, Levesque, Mitchell P., Dummer, Reinhard, Frederick, Dennie T., Flaherty, Keith T., Cooper, Zachary A., Wargo, Jennifer A., Wellbrock, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796027/
https://www.ncbi.nlm.nih.gov/pubmed/26977879
http://dx.doi.org/10.1016/j.ccell.2016.02.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796027/
https://www.ncbi.nlm.nih.gov/pubmed/26977879
http://dx.doi.org/10.1016/j.ccell.2016.02.003

Ejemplares similares